Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals

Journal of Virology

Volumn 75, Issue 5, 2001, Pages 2142-2153

  Engelmayer, J ^a   Larsson, M ^a   Lee, A ^a   Lee, M ^a   Cox, W I ^a   Steinman, R M ^a   Bhardwaj, N ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; IMMUNOSTIMULATION; INTERFERON PRODUCTION; MALE; POXVIRUS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRUS RESISTANCE;

ADULT; AIDS VACCINES; AVIPOXVIRUS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; DENDRITIC CELLS; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON TYPE II; MALE; MIDDLE AGED; POXVIRIDAE INFECTIONS; RANTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0035128160     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.75.5.2142-2153.2001     Document Type: Article

References (62)

1. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
2. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function
3. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation
4. Dendritic cells and the control of immunity
5. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gpl20 SF-2 recombinant vaccines in uninfected volunteers
6. + cytolytic T cell responses
7. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood
8. Help for cytotoxic T cell responses is mediated by CD40 signalling
9. + T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy
10. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
11. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gpl20, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group
12. Identification of RANTES, MIP-1 α and MIP-1 β as the major HIV-suppressive factors produced by CD8- T cells
13. Human cytotoxic T-cell memory: Long-lived responses to vaccinia virus
14. A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartment
15. Rapid generation of broad T-cell immunity in humans after single injection of mature dendritic cells
16. Mature dendritic cells boost functionally superior T cells in humans without foreign helper epitopes
17. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene
18. Vaccinia virus inhibits the maturation of human dendritic cells: A novel mechanism of immune evasion
19. + cytolytic T lymphocyte responses in seronegative volunteers
20. Cultured blood dendritic cells retain HIV-1 antigen-presenting capacity for memory CTL during progressive HIV-1 infection
21. Replication defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: Implications for antigen-specific immunotherapy
22. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers
23. + t cells provides a mechanism for lifelong persistance of HIV-1, even in patients on effective combination therapy
24. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
25. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
26. Vaccine-induced cytotoxic T lymphocytes against human immunodeflciency virus type I using two complementary in vitro stimulation stategies
27. TRANCE-RANK, a new signal pathway involved in lymphocyte development and T cell activation
28. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA
29. + T-cell depletion in simian immunodeficiency virus-infected macaques
30. Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiviral therapy
31. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses
32. Kinetics of gag-speclfic cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: A longitudinal analysis of rapid progressors and long-term asymptomatics
33. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis
34. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
35. + T cells in chronically infected HIV-1 positive individuals
36. + T cells
37. Progress in the development of an HIV-1 vaccine
38. Dendritic cells need T cell help to prime cytotoxic T cell responses to strong antigens
39. Cytotoxic-T cell responses viral load, and disease progression in early human immunodeficiency virus type 1 infection
40. Quantitation of HIV-1 specific cytotoxic T lymphocytes and plasma load of viral RNA
41. Decay kinetics of human immunodeficiency virus-specific cytotoxic T lymphocytes after combination antiretroviral therapy
42. Applications of pox virus vectors to vaccination: An update
43. HIV treatment failure: Testing for HIV resistance in clinical practice
44. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
45. + T helper and a T-killer cell
46. + T cell responses associated with control of viremia
47. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi
48. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gpl20 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection AIDS
49. Control of viremia in simian immunodeficiency virus infection by CD8(+) lymphocytes
50. T-cell help for cytotoxic T lympbocytes is mediated by CD40-CD40L interactions
51. Dendritic cells
52. Immune regulatory determine productive interactions within human T lymphocyte-dendritic cell clusters
53. +, interferon-γ-secreting, T lymphocytes
54. Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL
55. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in nonavian species
56. A novel assay for apoptosisflow cytometric detection of phosphatidylserine expression on early apoptotic cells using fiuorescein labeled Annexin V
57. β-Chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans
58. Association between HIV-specific T helper responses and CIL activities in pediatric AIDS
59. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
60. Efficient lysis of human immunodeficiency virus type-1 infected cells by cytotoxic T lymphocytes
61. Quantifying residual HIV-1 replication in patients receiving combination antiretrovlral therapy
62. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily